INCY Stock Overview
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for INCY from our risk checks.
Incyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.74 |
| 52 Week High | US$75.74 |
| 52 Week Low | US$50.27 |
| Beta | 0.67 |
| 1 Month Change | -9.99% |
| 3 Month Change | -15.07% |
| 1 Year Change | -29.63% |
| 3 Year Change | -39.05% |
| 5 Year Change | -34.43% |
| Change since IPO | 2,659.47% |
Recent News & Updates
Recent updates
Incyte: A Potential GARP Superstar
Feb 27Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Feb 02
Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Oct 31Knight's affiliate files for Brazilian approval of cancer drug tafasitamab
Oct 07Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
Sep 29Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia
Sep 15Incyte wins approval of Pemazyre for rare blood cancer
Aug 26Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%
Aug 02With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case
Jul 27Incyte Corp. Should Move Higher (Technical Analysis)
Jul 18Incyte: Growth Drivers Are Coming
Jun 17Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures
Apr 14Incyte: All Atention On Opzelura
Mar 21Incyte: Still Has Room To Grow
Jan 24Incyte: The Right Time To Buy The Stock
Dec 28Incyte: Not Exciting Yet, But Perhaps To Come
Aug 14Shareholder Returns
| INCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | 1.5% | 1.2% |
| 1Y | -29.6% | 1.1% | 24.7% |
Return vs Industry: INCY underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: INCY underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| INCY volatility | |
|---|---|
| INCY Average Weekly Movement | 2.9% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INCY has not had significant price volatility in the past 3 months.
Volatility Over Time: INCY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,524 | Herve Hoppenot | www.incyte.com |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
Incyte Corporation Fundamentals Summary
| INCY fundamental statistics | |
|---|---|
| Market cap | US$11.60b |
| Earnings (TTM) | US$597.60m |
| Revenue (TTM) | US$3.70b |
19.4x
P/E Ratio3.1x
P/S RatioIs INCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INCY income statement (TTM) | |
|---|---|
| Revenue | US$3.70b |
| Cost of Revenue | US$1.88b |
| Gross Profit | US$1.81b |
| Other Expenses | US$1.21b |
| Earnings | US$597.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 2.66 |
| Gross Margin | 49.00% |
| Net Profit Margin | 16.17% |
| Debt/Equity Ratio | 0% |
How did INCY perform over the long term?
See historical performance and comparison